Skip to Main Content

Biotech unicorn Moderna Therapeutics baffled its peers last month when it raised $500 million in a seventh round of venture financing. How, the question went, did the company sell investors on a $7.5 billion valuation despite outstanding questions about its science?

STAT obtained Moderna’s investor slide deck, one in which the company predicts billion-dollar futures for drugs only tested in mice and argues its vaccines business can bring in $15 billion in annual revenue.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED
  • Sounds like investors are getting either stupid or they have too much capital to throw away. Investing on a dec of slide which is 100000% based upon assumptions, not science and data.

Comments are closed.